Open-label, non-randomised, single centre study which will assess the presence of reovirus
(Reolysin®), following intravenous administration with or without Granulocyte-macrophage
colony-stimulating factor (GM-CSF) given to patients prior to surgery for metastatic
melanoma. All patients will receive an initial low 'immunisation' dose of intravenous
reovirus. Patients will be enrolled sequentially in to each of the two cohorts receiving
either reovirus alone, or reovirus plus GM-CSF. For this study we anticipate 8-16 evaluable
patients, up to 8 for each group. The endpoints of this study will compare the 2 treatment
groups for reovirus tumour infiltration and replication. Compare the neutralising antibody
development and cell-mediated immune response and identify any adverse events and laboratory
toxicities.